Skip to content
Screener

Tango Therapeutics TNGX Q1 2026 earnings

Reported May 13, 2026 · Before market open

Revenue-
EPS-$0.32In line
EPS estimate-$0.32

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$3.3M
EPS estimate-$0.34

Financials

Q1 2026

Income statement

See full
Revenue--100%
Operating income-$48.8M-14.7%
Net income-$45.5M-14.1%
EPS (diluted)-$0.32+11.1%

Balance sheet

See full
Cash & equivalents$160.0M+162%
Total debt$32.8M-11.3%
Total equity$391.5M+135%
Total assets$435.8M+58.9%

Cash flow

See full
Operating cash flow-$44.4M-6.4%
CapEx-$2.0K-104%
Free cash flow-$44.4M-6.3%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$2.99B+1,915%
Enterprise value$2.86B+2,204%
P/S52.4×+48.8×

Profitability

See full
Operating margin-206.2%-61.0pp
Net margin-188.2%-55.4pp
FCF margin-250.1%-49.4pp

Returns & leverage

See full
Return on equity-38.4%-10.5pp
Debt / equity0.1×-0.1×
Current ratio27.4×+21.1×

FAQ

When did Tango Therapeutics report Q1 2026 earnings?
Tango Therapeutics (TNGX) reported Q1 2026 earnings on May 13, 2026 before market open.
What were Tango Therapeutics's Q1 2026 revenue and EPS?
Tango Therapeutics reported revenue of - and eps of $-0.32 for Q1 2026.
Did Tango Therapeutics beat estimates in Q1 2026?
EPS beat the consensus estimate of $-0.32 by $0.00.
How did Tango Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 100.0% from $5.4M a year earlier and eps grew 11.1% from $-0.36.
Where can I find Tango Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-221677) and the 10-Q periodic report (0001193125-26-221656) directly on SEC EDGAR. The filing index links above go to sec.gov.